title: How endemic countries can accelerate lymphatic filariasis elimination? An analytical review to identify strategic and programmatic interventions.
abstract: Lymphatic filariasis (LF) is endemic in 81 countries in the world, and a number of these countries have targeted for LF elimination. This review of literature and analysis was conducted to identify additional and sustainable strategies to accelerate LF elimination from endemic countries. This review noted that adverse events due to mass drug administration (MDA) of diethyl carbamazine (DEC) tablets, poor knowledge and information about LF amongst health workers & community members, and limited focus on information, education & communication (IEC) activities and interpersonal communication are the major barriers in LF elimination. The new approaches to increase compliance with DEC tablets (including exploring the possibility for DEC fortification of salt), targeted education programmes for physicians and health workers, and IEC material and inter personal communication to improve the knowledge of community are immediately required. There is a renewed and pressing need to conduct operational research, evolve sustainable and institutional mechanisms for education of physicians and health workers, ensure quality of trainings on MDA, strengthen IEC delivery mechanisms, implement internal and external monitoring of MDA activities, sufficient funding in timely manner, and to improve political and programmatic leadership. It is also time that lessons from other elimination programmes are utilized to accelerate targeted LF elimination from the endemic countries.
authors.affiliation: Write Health Society for Community Health Actions, Gwalior, India. c.lahariya@gmail.com
authors.forename: Chandrakant
authors.initials: C
authors.lastname: Lahariya
authors.forename: Shailendra S
authors.initials: SS
authors.lastname: Tomar
mesh_terms: D003140:Communicable Disease Control / Q000379:methods*; D004049:Diethylcarbamazine / Q000008:administration & dosage / Q000009:adverse effects; D004605:Elephantiasis, Filarial / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control* / Q000523:psychology; D019353:Endemic Diseases / Q000517:prevention & control*; D006266:Health Education; D006282:Health Personnel / Q000193:education / Q000523:psychology; D006801:Humans
chemical_list: D004049:Diethylcarbamazine